methyl 2-trifluoromethanesulfonyloxypropionate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: methyl 2-trifluoromethanesulfonyloxypropionate
• 英文别名: Propanoic acid, 2-[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester, (2S)-；methyl 2-(trifluoromethylsulfonyloxy)propanoate
• 化学式: C₅H₇F₃O₅S
• 分子量: 236.169
• InChiKey: GAIWVDWTECBESF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 2-trifluoromethanesulfonyloxypropionate 在 potassium fluoride 作用下， 以 水 为溶剂， 反应 5.0h， 以19%的产率得到2-氟丙酸甲酯
  参考文献：
  名称：

  Method for preparing a fluorinated organic compound

  摘要：

  一种从含有至少一个亲核离开基团Nu的有机化合物(I)制备氟化有机化合物(II)的方法，以及制备不同特定有机化合物，特别是氟甲基吡唑化合物的方法。该方法包括：在水的存在下，有机化合物(I)与至少提供至少一个氟化物阴离子的盐的反应；以及将化合物(I)中至少一个亲核离开基团Nu替换为氟原子，以获得氟化有机化合物(II)。

  公开号：

  US20140148603A1
• 作为产物：
  描述：

  三丁基乙烯基锡 、 1-tert-butoxycarbonyl-4-{4-[1(S)-(4-bromophenyl)-ethyl]-3(R)-methylpiperazin-1-yl}-piperidine 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 生成 methyl 2-trifluoromethanesulfonyloxypropionate
  参考文献：
  名称：

  MCH antagonists for the treatment of obesity

  摘要：

  本发明公开了使用黑素浓缩激素（MCH）拮抗剂治疗肥胖、代谢紊乱、食欲紊乱（如过度进食）和糖尿病的方法，以及作为黑素浓缩激素（MCH）拮抗剂的新化合物。在其他方面，本发明涉及包含这种MCH拮抗剂的药物组合物，以及制备这种化合物的方法。本发明的化合物通常具有以下结构： 其中取代基如本文所定义。

  公开号：

  US20050004121A1

文献信息

• Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria
  作者：Gian Marco Elisi、Annalida Bedini、Laura Scalvini、Caterina Carmi、Silvia Bartolucci、Valeria Lucini、Francesco Scaglione、Marco Mor、Silvia Rivara、Gilberto Spadoni

  DOI：10.3390/molecules25184057

  日期：——

  nitrogen and conformational equilibria were investigated by NMR spectroscopy and molecular dynamics simulations. Receptor affinity was conserved only for the beta-methyl derivative, which also showed significant stereoselectivity, with the (S) enantiomer being the eutomer. Molecular dynamics simulations, validated by NMR spectroscopy, showed that the beta-methyl group affects the conformational preferences

  N-苯胺基乙酰胺是一类褪黑激素能药物，其苯胺部分模仿天然配体的吲哚环，乙酰胺链再现褪黑激素的吲哚环。此类中最简单的化合物 N-2-[(3-甲氧基苯基) 甲基氨基]乙基}乙酰胺 (UCM793)，对 MT1 和 MT2 膜受体具有纳摩尔的结合亲和力。为了探索链构象对受体结合的影响，将甲基插入到酰胺氮的亚甲基 α 或 β 上，并通过 NMR 光谱和分子动力学模拟研究了构象平衡。受体亲和力仅对 β-甲基衍生物是保守的，它也显示出显着的立体选择性，其中 (S) 对映异构体是 eutomer。分子动力学模拟，经核磁共振波谱验证，表明β-甲基影响乙酰胺链的构象偏好。对接受体晶体结构为观察到的手性识别提供了基本原理，表明 (S)-β-甲基有利于更适合受体结合位点的构象。
• 5-HT_1A- versus D₂-Receptor Selectivity of Flesinoxan and Analogous <i>N</i> ⁴-Substituted <i>N</i> ¹-Arylpiperazines
  作者：Wilma Kuipers、Chris G. Kruse、Ineke van Wijngaarden、Piet J. Standaar、Martin Th. M. Tulp、Nora Veldman、Anthony L. Spek、Adriaan P. IJzerman

  DOI：10.1021/jm960496o

  日期：1997.1.1

  We investigated the structural requirements for high 5-HT1A affinity of the agonist flesinoxan and its selectivity versus D-2 receptors. For this purpose a series of arylpiperazine congeners of flesinoxan were synthesized and evaluated for their ability to displace [H-3]-8-OH-DPAT and [H-3]spiperone from their specific binding sites in rat frontal cortex homogenates and rat striatum, respectively. Variations were made in the N-4-substituent and the arylpiperazine region. Effects of N-4-substitution in the investigated compounds appeared to be quite similar for 5-HT1A- and D-2-receptor affinity. Lipophilicity at a distance of four carbon atoms from the piperazine N-4 atom seems to be the main contributing factor to affinity for both receptors. Our data show that the amide group in the flesinoxan N-4-substituent is unlikely to interact with the 5-HT1A receptor but, instead, acts as a spacer. In contrast to the structure-affinity relationships (SARs) of the N-4-substituents, selectivity for 5-HT1A versus D-2 receptors was gained by the arylpiperazine substitution pattern of flesinoxan. Restriction of flexibility of the N-4-(benzoylamino)ethyl substituent and its effect on 5-HT1A-receptor affinity and activity were also studied. Our data show that in the bioactive conformation, the N-4-[(p-fluorobenzoyl)amino]ethyl substituent is probably directed anti-periplanar relative to the H-N4 atom. These results were used to dock flesinoxan (1) and two of its congeners (27 and 33) into a model of the 5-HT1A receptor that we previously reported. Amino acid residues surrounding the N-4-[(p-fluorobenzoyl)amino]ethyl substituent of flesinoxan and its congeners are also present in D-2 receptors. In contrast, several residues that contact the benzodioxane moiety differ from those in D-2 receptors. These observations from the 3D model agree with the 5-HT1A SAR data and probably account for the selectivity of flesinoxan versus D-2 receptors.
• p38 MAP kinase inhibitors: Metabolically stabilized piperidine-substituted quinolinones and naphthyridinones
  作者：Jianming Bao、Julianne A. Hunt、Shouwu Miao、Kathleen M. Rupprecht、John E. Stelmach、Luping Liu、Rowena D. Ruzek、Peter J. Sinclair、James V. Pivnichny、Cornelis E.C.A. Hop、Sanjeev Kumar、Dennis M. Zaller、Wesley L. Shoop、Edward A. O’Neill、Stephen J. O’Keefe、Chris M. Thompson、Rose M. Cubbon、Ruixiu Wang、Wen Xiao Zhang、James E. Thompson、James B. Doherty

  DOI：10.1016/j.bmcl.2005.09.065

  日期：2006.1

  Quinolinones and naphthyridinones with C7 N-t-butyl piperidine substituents were found to be potent p38 MAP kinase inhibitors. These compounds significantly suppress TNF-alpha release in both cellular and LPS-stimulated whole blood assays. They also displayed excellent PK profiles across three animal species. Quinolinone 4f at 10 mpk showed comparable oral efficacy to that of dexamethasone at 1 mpk in a murine collagen-induced arthritis model. (c) 2005 Elsevier Ltd. All rights reserved.
• WO2023/214552
  申请人：——

  公开号：——

  公开（公告）日：——
• MCH antagonists for the treatment of obesity
  申请人：Palani Anandan

  公开号：US20050004121A1

  公开（公告）日：2005-01-06

  The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.

  本发明公开了使用黑素浓缩激素（MCH）拮抗剂治疗肥胖、代谢紊乱、食欲紊乱（如过度进食）和糖尿病的方法，以及作为黑素浓缩激素（MCH）拮抗剂的新化合物。在其他方面，本发明涉及包含这种MCH拮抗剂的药物组合物，以及制备这种化合物的方法。本发明的化合物通常具有以下结构： 其中取代基如本文所定义。